Τίτλος:
PCSK9 Antibody-based treatment strategies for patients with statin intolerance
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Statin intolerance refers to the inability of a patient to tolerate statin therapy, presenting muscle aches, pains, weakness and muscle inflammation. Thus, numerous patients are not treated with suitable statinbased therapy or take only very low doses. As a result, the desired decrease in low-density lipoprotein cholesterol (LDLC) is not achieved, resulting in patients at a high risk for cardiovascular events, requiring an alternative lipidlowering treatment. Common treatments manage to reduce the LDL-C level by up to 20%. Recently, new alternative treatment options have been proved to lower the LDL-C level by up to 70%. These treatment strategies are based on human monoclonal antibodies against protein convertase subtilisin/kexin 9 (PCSK9). Materials and Methods: Herein, we review the efficiency of anti-PCSK9 in treatment of hypercholesterolemic patients with statin intolerance. We focused on the use of PCSK9 inhibitors in statin-intolerant patients and we estimated the clinical results concerning the reduction of the mean LDL-C concentration and the side effects that were observed. Results: In the majority of cases, treatment strategy based on PCSK9 was successful and achieved the end-points. Conclusion: PCSK9 inhibition can be considered as a treatment of option for lipid-lowering in statin-intolerant patients. © 2021 International Institute of Anticancer Research. All rights reserved.
Συγγραφείς:
Voutyritsa, E.
Damaskos, C.
Farmaki, P.
Kyriakos, G.
Diamantis, E.
Quiles-Sanchez, L.V.
Garmpi, A.
Garmpis, N.
Patsouras, A.
Stelianidi, A.
Savvanis, S.
Περιοδικό:
In vivo (Athens, Greece)
Εκδότης:
International Institute of Anticancer Research
Λέξεις-κλειδιά:
alirocumab; evolocumab; ezetimibe; fenofibrate; human monoclonal antibody; hydroxymethylglutaryl coenzyme A reductase inhibitor; hypocholesterolemic agent; low density lipoprotein cholesterol; proprotein convertase 9; proprotein convertase 9 inhibitor; unclassified drug; hydroxymethylglutaryl coenzyme A reductase inhibitor; hypocholesterolemic agent; monoclonal antibody; PCSK9 protein, human; proprotein convertase 9; subtilisin, cholesterol blood level; drug efficacy; drug hypersensitivity; drug safety; drug utilization review; human; hypercholesterolemia; muscle disease; Review, Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9; Subtilisin
DOI:
10.21873/INVIVO.12232
